“According to analysis led by Kanika Bahl and Pooja Shaw of Results for Development’s (R4D’s) Market Dynamics team, improved global incentives and information on cost-effectiveness could save the fight against malaria up to $630 million over the next five years and encourage manufacturers to produce better-performing nets,” Bahl, a managing director for R4D, and Shaw, a program officer in the Market Dynamics Practice at R4D, write in the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog. “Using their central position in global [long-lasting insecticide-treated net (LLIN)] markets, donor institutions can introduce policy incentives to focus on cost-effectiveness and rationalize specifications so that suppliers can take advantage of economies of scale in production,” they continue, adding, “To implement these policies, global guidance on the performance of various nets is urgently needed, and this is where organizations such as the WHO can provide direction” (8/27).
The U.S. Government Accountability Office (GAO) recently released two reports on issues related to global health. In “Ensuring Drug Quality in Global Health Programs,” the agency writes, “Concerns have been raised about the potential for substandard drugs to enter the supply chains of global health programs,” and notes that it concluded, “U.S.-funded global health programs have put regulatory and policy requirements in place to help prevent procurement of substandard drugs” (8/1). In another report looking at the WHO, titled “Reform Agenda Developed, but U.S. Actions to Monitor Progress Could be Enhanced,” GAO found, “The United States has provided input into WHO’s reform agenda, particularly in the areas of transparency and accountability, but the Department of State’s (State) tool for assessing progress in the area of management reform could be enhanced” (7/23).
Also In Global Health News: Breast Cancer In Developing World; Burkina Faso ITN Distribution; Diarrhea In People Over Age Five; Gates Q&A
Researchers Highlight ‘Troubling Increase’ In Breast Cancer In Developing Countries “International cancer specialists meet this week to plan an assault on a troubling increase of breast cancer in developing countries, where nearly two-thirds of women aren’t diagnosed until it has spread through their bodies,” the Associated Press reports. Researchers will…
Subsidized artemisinin-based combination therapies (ACTs) under the Affordable Medicines Facility – malaria (AMFm) program will be available in select countries “in two week’s time,” SABC News reports. The announcement came Monday at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya.
Global Fund Approves ‘In Principle’ $47M Grant For Reducing Spread Of HIV Among MSM, Transgender In South Asia
The Global Fund to Fight AIDS, Tuberculosis and Malaria has approved, “in principle,” a $47 million grant to reduce the spread of HIV among gay and other men who have sex with men in seven south Asian countries, IANS/Thaindian.com reports.
TIME reports on evidence along the Thai-Cambodia border that the malaria parasite is gaining resistance to artemisinin â€“ “the only remaining effective drug in the world’s arsenal against malaria’s most deadly strain.”
During its recent board meeting in Addis Ababa, Ethiopia, the Global Fund to Fight AIDS, Tuberculosis and Malaria approved $2.4 billion for the three diseases, PlusNews reports. The money is for the fund’s “ninth round of grants, bringing the total amount of approved funding since its inception in 2001 to $18.4 billion,” according to the publication.
Also In Global Health News: Home HIV Treatment; Voluntary Testing In Kenya; Women/HIV Scorecard; Global Fund Zimbabwe Grant; Contraceptives In Tanzania
Home Vs. Clinic Treatment of HIV In Uganda The New York Times reports on a Lancet studyÂ that found treating Ugandan HIV patients at home is cheaper and just as effective as treating them in a clinic. “The finding is important because five million more Africans will need AIDS drugs in…
“The Global Fund to Fight AIDS, Tuberculosis and Malaria [on Monday] released the funding recommendations of its Technical Review Panel for the Transitional Funding Mechanism,” the Stop TB Partnership reports in an article on its webpage. “Grant proposals for tuberculosis (TB) received 25 percent ($127.4 million) of all the approved funding ($510 million) — a marked increase over the historic average share of 16 percent since the Global Fund was established in 2002,” the article notes, adding, “TB applications were also most successful, with an 86 percent recommendation rate; malaria applications engendered a 79 percent recommendation rate and HIV proposals a 62 percent recommendation rate” (8/21).
In this post in Huffington Post’s “Impact” blog, Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, examines “the success of U.S. efforts to promote better global health through support for [PEPFAR] and the Global Fund to Fight AIDS, Tuberculosis and Malaria.” She highlights U.S. Secretary of State Hillary Clinton’s recent trip to Africa, writing that Clinton’s “encouraging words” at the Reach Out Mbuya health center in Uganda reinforced U.S. commitment to an AIDS-free generation. She notes both PEPFAR and the Global Fund have supported the center and adds that “through hundreds of similar local programs all over the world, the Global Fund provides treatment to 3.6 million people who are HIV-positive.”